Physician profile
Richard E Ando
NPI 1689681439
$5,151.51
in general payments reported to CMS, 2019-2025
16 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $47.09 · 2021: $265 · 2022: $761 · 2023: $404 · 2024: $690 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Education: $25.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.27 |
| Education | $25.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,277.34 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,098.98 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,025.69 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $548.84 | 2019-2025 | Xolair |
| Genzyme Corporation | $342.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.26 | 2019-2023 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $173.65 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $156.41 | 2022-2025 | Orladeyo |
| Pfizer INC. | $99.87 | 2022 | |
| Pharming Healthcare, INC. | $65.26 | 2021 | |
| Leo Pharma INC. | $42.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.20 | 2019-2021 | |
| Lilly USA, LLC | $34.59 | 2024 | Ebglyss |
| Cycle Pharmaceuticals INC | $29.95 | 2025 | Sajazir |
| Galderma Laboratories, L.P. | $29.61 | 2025 | Nemluvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.